Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2014 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (291)	4/22/2014 8:42:14 AM
From: Robohogs	Respond to of 487

Might be interesting to take a poll on YE numbers - can we bounce? With Yellen being easy (not like that), I think we can. Jon

To: BulbaMan who wrote (291)	4/22/2014 11:44:23 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 487

Really interesting choice. I spent hours last night looking at the imaging stuff and the orphan designation. Thank you, Marty! Rick

To: BulbaMan who wrote (291)	4/30/2014 2:58:46 PM
From: Arthur Radley	Respond to of 487

As of today I'm into the June FDA OIC meeting three ways, as I bought a few PGNX shares @$3.40. I've owned Salix for many years, plus I've owned NKTR for a long time. The FDA meeting will impact all three companies--short-term PGNX should get a nice bounce assuming the FDA goes along with the AEs seen in the PGNX/Salix drug. If they get over this hurdle IMO the NKTR/AZN drug will garner most of the business---but this approval will come later than the PGNX drug.